Peptide Profile: VIP5
VIP5, or Vasoactive Intestinal Peptide 5, is a synthetic analog of the naturally occurring vasoactive intestinal peptide (VIP). This peptide plays a significant role in modulating various physiological processes, including vasodilation, immune regulation, and neurological signaling. VIP5 is specifically engineered to enhance these natural properties, making it a valuable tool in medical research and therapeutic applications.
Key Components and Mechanism:
- Structure: VIP5 is a modified version of the endogenous peptide VIP, designed to improve stability and receptor affinity while maintaining its biological activity.
- Mechanism of Action: VIP5 primarily acts on VPAC1 and VPAC2 receptors, which are widely distributed in the body. Binding to these receptors initiates a cascade of intracellular signaling pathways that regulate vascular tone, immune responses, and neuronal communication.
Applications:
- Neurological Health: VIP5 has shown potential in modulating neurotransmitter release, offering therapeutic applications for neurodegenerative diseases like Alzheimer’s and Parkinson’s.
- Immune Modulation: By regulating cytokine production and inflammatory responses, VIP5 may be beneficial in treating autoimmune and inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease.
- Cardiovascular Support: Its vasodilatory effects improve blood flow and may aid in managing conditions like hypertension and pulmonary arterial hypertension.
Benefits and Considerations:
VIP5 is notable for its potent biological effects and targeted action. Its enhanced stability allows for prolonged activity, making it suitable for research and clinical trials. Potential side effects include localized reactions or mild systemic effects, which depend on dosage and delivery method.
VIP5 continues to be a focus of research due to its diverse therapeutic potential, offering promising applications in neurology, immunology, and cardiovascular medicine.
Peptide Profile: VIP5
References
Dickson, L., & Finlayson, K. (2009). VPAC and PAC receptors: From ligands to function. Pharmacology & Therapeutics, 121(3), 294–316. https://doi.org/10.1016/j.pharmthera.2008.11.006
Gozes, I., & Furman, S. (2003). VIP and related peptides: Potential modulators of inflammatory and degenerative diseases. Immunology Letters, 85(2), 149–154. https://doi.org/10.1016/S0165-2478(02)00222-5
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000). The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocrine Reviews, 21(6), 619–670. https://doi.org/10.1210/edrv.21.6.0415
Waschek, J. A. (2013). VIP and PACAP: Neuroprotective peptides with therapeutic potential in acute and chronic neurodegenerative diseases. Current Pharmaceutical Design, 19(15), 2495–2512. https://doi.org/10.2174/1381612811319150015
Ruhmann, A., Schally, A. V., & Havt, A. (2007). Targeting receptors for VIP and PACAP with agonists and antagonists: New molecular tools for the study of cancer and neurobiology. Peptides, 28(9), 1838–1849. https://doi.org/10.1016/j.peptides.2007.05.015
